US Patent Issued to Genzyme on Jan. 20 for "Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors" (New Jersey, Massachusetts Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,737, issued on Jan. 20, was assigned to Genzyme Corp. (Cambridge, Mass.).

"Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors" was invented by Harvey Lieberman (Bridgewater, N.J.), Donglai Yang (Bridgewater, N.J.), C. Michael Philbrook (Boston), Michael Santos (Cambridge, Mass.) and Chris Ho (Bridgewater, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Pharmaceutical formulations with a tropomyosin-related kinase inhibitor ("Trk inhibitor") are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline s...